GLP-1 Drugs Now Stand at the Centre of a Multi-Disease Treatment Revolution
Publication: Pharmaceutical Technology Focus
Green chemistry principles for a sustainable future in pharma
Green chemistry principles have moved from being a “nice to have” idea to a practical framework that shapes how molecules are discovered, developed and manufactured.
Integrated Drug Discovery: why expertise matters
See how chemistry, biology, DMPK, and DMTA expertise with a trusted preclinical CRO make integrated drug discovery faster and more reliable. Read now.
A step-by-step guide for conducting safe and successful bile duct cannulated PK studies
In recent years, the biopharmaceutical industry has increasingly focused on reducing animal testing when conducting safety and efficacy studies for new drugs. Ethical considerations, regulatory guidelines, and advancements in alternative testing methods like artificial intelligence have driven this shift.
Bispecific antibodies: engineering complexity into simplicity
Clear guidance on bispecific antibodies, from formats and engineering to analytics and control strategy, for scalable development and manufacturing. Read now.
Integrated Expertise for Complex Modalities: Driving Innovation in Molecular Glue Discovery
Prove induced proximity in molecular glues with ITC, fluorescence polarization, and co-IP. Practical steps for stronger discovery decisions. Read the guide.
Translational and Clinical Research services
Syngene’s data consortium comprises a group of consenting clients working towards greater learning through predictive modeling to enable faster drug discovery.
GLP-certified viral testing and clearance services
Syngene offers GLP-certified viral testing and clearance services with flexible scheduling and rapid turnaround, supporting over 100 global clinical programs. Their facility is India’s only GLP-certified site for viral safety studies, ensuring compliance with FDA, EMA, and WHO regulations. Services include viral clearance studies, cell bank testing, and in-process/batch testing for biologics.
Your one-stop-shop for mAb clinical and commercial manufacturing
Every biologics journey begins with uncertainty. That’s why, at Syngene, we take the first step for you. We initiate Cell Line Development immediately, saving you up to four months while you secure approvals and funding. This early action places your program on a solid footing, reducing both technical and timeline risks. This isn’t just a […]
Transforming Cell Line Development with Syngene’s SynWeave™ Platform
Built on a proprietary CHO cell line and transposon-based technology, SynWeave™ enables the rapid generation of high-yield, stable, and homogeneous clones. The platform integrates advanced clone screening using the Ambr-250 bioreactor, allowing for comprehensive evaluation of titer, key product quality attributes, and process parameters, accelerating your path to robust cell line development.